Robert J Dennis $HCA SEC Form 4 Insider Trading

Robert J Dennis has filed a total of 0 insider trades in $HCA since 2021. Their most recent trade was a of shares, made on . Their largest trade was a of shares, made on . We estimate that they now own 26,601 shares of $HCA, worth an estimated $10.2 million.

Insider Trading at $HCA

There have been a total of 129 insider trades reported at $HCA since 2021, with 95,131 shares purchased and 516,649 shares sold. The most active insider traders in $HCA stock have been Kathryn A. Torres, Kathleen M Whalen, and Michael S. Cuffe. The most recent trade was a sale of 15,698 shares reported by Jon M Foster (EVP and COO), made on May 13, 2025.

$HCA Executives and Stock Owners with Insider Trades

• Kathryn A. Torres, SVP-Payer Contracting & Align.

• Kathleen M Whalen, SVP & Chief Ethics Officer

• Michael S. Cuffe, EVP and Chief Clinical Officer

• Charles J Hall, Group President

• P. Martin Paslick, SVP and CIO

• Jane D. Englebright, SVP and Chief Nursing Officer

• Jonathan B Perlin, Pres-Clinical Operations & CMO

• Christopher F. Wyatt, SVP & Controller

• Jennifer Berres, SVP & Chief Human Res. Officer

• Bill B Rutherford, CFO and EVP

• Joseph A Iii Sowell, SVP; Chief Development Officer

• Samuel N Hazen, CEO

• Phillip G Billington, SVP-Internal Audit Services

• A Bruce Jr Moore, Group President - Service Line

• Jon M Foster, Group President

• Erol R Akdamar, Group President

• Deborah M Reiner, SVP - Mktg. & Communications

• Chad J Wasserman, SVP and CIO

• Jon M Foster, EVP and COO

• Jeffrey E. Cohen, SVP-Government Relations

• Timothy M Mcmanus, Group President

• Michael R Mcalevey, SVP & Chief Legal Officer

• Michael S. Cuffe, President-Physician Services

• Sammie S Mosier, SVP & Chief Nurse Executive

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.